Development of an HIV-vaccine based on antiidiotypic antibodies
Abstract
Anti-idiotypic antibodies are directed against the antigen binding domain of an antibody and are able to display the structure of the antigen. Therefore, the concept of vaccination with an anti-idiotypic antibody against the neutralising anti-HIV-1 mAb 2F5 and such mimicking a highly conserved epitope was actualised with the establishment of the anti-idiotypic antibody Ab2-3H6. This murine antibody was developed at our institute in a previous FWF project: Ab2-3H6 is able to induce a humoral immune response with HIV-neutralising titres in the animal model confirming the therapeutic potential. Further development of this antibody requires switching the mouse antibody to a chimeric human/mouse molecule to prevent the generation of human anti-mouse antibodies (HAMAs) in man.
HIV-vaccine anti-idiotypic antibodies humorale immune response
Publikationen
Expression of a Fab Fragment in CHO and Pichia pastoris. A Comparative Case Study
Autoren: Renate Kunert, Johannes Gach, Hermann Katinger Jahr: 2008
Journal articles
Expression, purification, and in vivo administration of a promising anti-idiotypic HIV-1 vaccine.
Autoren: Gach, JS; Quendler, H; Ferko, B; Katinger, H; Kunert, R Jahr: 2008
Journal articles
Humanization variants of an anti-idiotypic antibody
Autoren: Renate Kunert, Alexander Mader, Hermann Katinger Jahr: 2010
Conference & Workshop proceedings, paper, abstract
Project staff
Renate Kunert
Univ.Prof. Dipl.-Ing. Dr.nat.techn. Renate Kunert
renate.kunert@boku.ac.at
Tel: +43 1 47654-79852
Project Leader
15.12.2003 - 14.12.2006